Gilead
New data shows Gilead’s remdesivir “potently inhibited” SARS-CoV-2 in human lung cell cultures
July 10, 2020Medical Communications, Research and Development COVID-19, Gilead, coronavirus, remdesivir
New findings published from researchers at Vanderbilt University Medical Center (VUMC) at the University of North Carolina, as well as …
Gilead acquires 49.9% of Pionyer Therapeutics in potential $1.5bn+ deal
June 24, 2020Research and Development, Sales and Marketing Gilead, Pionyr, pharma
Gilead has announced its intention to acquire 49.9% of shares in cancer immunotherapy specialist Pionyr Therapeutics with a payment of …
Gilead to investigate inhaled formulation of promising COVID-19 therapy remdesivir
June 23, 2020Manufacturing and Production, Research and Development COVID-19, Gilead, remdesivir
Gilead is intent on pushing the applications of its antiviral drug remdesivir after it has shown efficacy in the treatment …
EMA could approve Gilead’s streamlined remdesivir application for COVID-19 “within weeks”
June 9, 2020Manufacturing and Production, Sales and Marketing COVID-19, EU, Gilead, coronavirus, remdesivir
The European Medicines Agency has received the application from Gilead for the first conditional marketing authorisation (CMA) of its antiviral …
Australian Taskforce recommends Gilead’s remdesivir for routine use in the country’s COVID-19 patients
June 5, 2020Medical Communications, Sales and Marketing Australia, COVID-19, Gilead, coronavirus, remdesivir
Australia could be set to follow the decisions of other nations around the world in officially licensing Gilead’s antiviral therapy …
India and South Korea approve Gilead’s remdesivir for emergency use against COVID-19
June 3, 2020Research and Development, Sales and Marketing COVID-19, Gilead, India, coronavirus, remdesivir, south korea
India and South Korea have moved to follow in the footsteps of the US in approving Gilead’s antiviral therapy remdesivir …
Five-day remdesivir regimen shows promising clinical benefit in COVID-19 patients, Phase 3 data shows
June 2, 2020Manufacturing and Production, Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir
Gilead has unveiled eagerly anticipated new Phase 3 data on the addition of its antiviral therapy remdesivir to standard of …
Gilead’s magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at ASCO 2020
June 1, 2020Research and Development, Sales and Marketing ASCO 2020, Cancer, Gilead, leukaemia, magrolimab
Gilead took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to unveil new Phase 1b …
First ever benefit-risk analysis is “favourable” for remdesivir as COVID-19 treatment
May 29, 2020Medical Communications, Research and Development COVID-19, DSRU, Gilead, coronavirus, pharma, remdesivir
The UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s …
Japan authorises exceptional approval of Gilead’s remdesivir for severe COVID-19
May 12, 2020Manufacturing and Production, Sales and Marketing COVID-19, Gilead, Japan, coronavirus, pharma, remdesivir
Remdesivir, perhaps the leading hope in the race against COVID-19, has secured approval from Japan’s Ministry of Health, Labour and …
FDA approves emergency use of Gilead’s remdesivir for hospitalised COVID-19 patients
May 4, 2020Sales and Marketing COVID-19, FDA, Gilead, coronavirus, remdesivir
Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one …
Top Ten most popular articles on Pharmafile.com this week
May 1, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Gilead, UK, coronaviurs
The search for a COVID-19 treatment has ramped up this week, with two new studies detailing the efficacy of Gilead’s …
Two studies reveal “positive” data for Gilead’s remdesivir in hospitalised COVID-19 patients
April 30, 2020Research and Development COVID-19, Gilead, coronavirus, remdesivir
The first findings of two new studies have been revealed detailing the efficacy of Gilead’s antiviral therapy remdesivir in the …
Leading COVID-19 hope remdesivir fails to provide clinical benefit in first randomised trial
April 24, 2020Medical Communications, Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir
Gilead’s remdesivir, which has been hailed as one of the few truly promising treatments for COVID-19 at this early stage …
Gilead’s remdesivir significantly reduces COVID-19 symptoms in rhesus monkeys in NIH trial
April 20, 2020Business Services, Medical Communications, Sales and Marketing COVID-19, Gilead, National Institutes of Health, coronavirus, remdesivir
A study from the National Institutes of Health has shed more light on the efficacy of Gilead’s promising antiviral therapy …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
